Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery.
Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, Görlich D, Kellum JA, Zarbock A. · 2014
Read Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. by Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, Görlich D, Kellum JA, Zarbock A. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3968141.txt.
Introduction
Melanie Meersch and colleagues test a urine test for early warning of kidney injury after heart surgery, in PLoS ONE in 2014. Acute kidney injury is common after operations using a heart-lung machine, but the standard blood marker, creatinine, rises only one to three days later, too late for prevention. The test measures two proteins, TIMP-2 and IGFBP7, that pause cell division, an early stress response in injured kidney cells. Fifty high-risk patients gave serial urine samples.
Twenty-six patients developed kidney injury. The urine marker multiplied rose within four hours of surgery in those patients, and its peak in the first day predicted injury with good accuracy, 92 percent sensitivity at the chosen cutoff. Falling marker values were the strongest sign the kidney would recover. The authors present the pair as an early alarm and recovery gauge.
Catalog record
| CREATOR | Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, Görlich D, Kellum JA, Zarbock A. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Urinary TIMP-2 and IGFBP7 as Early Biomarkers of Acute Kidney Injury and Renal Recovery following Cardiac Surgery By Melanie Meersch, Christoph Schmidt, Hugo Van Aken, Sven Martens, Jan Rossaint, Kai Singbartl, Dennis Görlich, John A Kellum, Alexander Zarbock, Peter Rosenberger Published in: PLoS ONE DOI: 10.1371/journal.pone.0093460 ABSTRACT Abstract Background Difficulties in prediction and early identification of (acute kidney injury) AKI have hindered the ability to develop preventive and therapeutic measures for this syndrome. We tested the hypothesis that a urine test measuring insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in acute kidney injury (AKI), could predict AKI in cardiac surgery patients. Methods We studied 50 patients at high risk for AKI undergoing cardiac surgery with cardiopulmonary bypass (CPB). Serial urine samples were analyzed for [TIMP-2]*[IGFBP7] concentrations. The primary outcome measure was AKI as defined by international consensus criteria following surgery. Furthermore, we investigated whether urine [TIMP-2]*[IGFBP7] could predict renal recovery from AKI prior to hospital discharge. Results 26 patients (52%) developed AKI. Diagnosis based on serum creatinine and/or oliguria did not occur until 1–3 days after CPB. In contrast, urine concentration of [TIMP-2]*[IGFBP7] rose from a mean of 0.49 (SE 0.24) at baseline to 1.51 (SE 0.57) 4 h after CPB in patients who developed AKI. The maximum urinary [TIMP-2]*[IGFBP7] concentration achieved in the first 24 hours following surgery (composite time point) demonstrated an area under the receiver-operating characteristic curve of 0.84. Sensitivity was 0.92, and specificity was 0.81 for a cutoff value of 0.50. The decline in urinary [TIMP-2]*[IGFBP7] values was the strongest predictor for renal recovery. Conclusions Urinary [TIMP-2]*[IGFBP7] serves as a sensitive and specific biomarker to predict AKI early after cardiac surgery and to predict renal recovery. Clinical Trial Registration Information: www.germanctr.de/, DRKS-ID: DRKS00005062 INTRODUCTION Acute kidney injury (AKI) is a common and serious complication after cardiac surgery [1]. It may occur in over 40% of adults, with 1–5% requiring renal replacement therapy (RRT) [2]–[4]. After cardiac surgery, small creatinine increases of 20–25% from preoperative baseline are associated with adverse outcomes [3], [5]. The mortality in cardiac surgery patients with a severe, RRT-requiring AKI can be as high as 60% [3], [4], [6]. Although some clinical tools and scores exist to predict and stratify AKI, we are still lacking biomarkers to predict AKI and recovery from AKI early enough for interventions to be likely effective. The incidence and severity of AKI and patients outcome have not changed in recent years [1], [7], [8]. Currently, diagnosing and staging of AKI are exclusively based on elevations in serum creatinine and/or decreases in urine output. Serum creatinine, however, is widely known to be insensitive to acute changes in kidney function [9]. Serum creatinine concentrations neither accurately reflect the glomerular filtration rate nor do they point to the degree of tubular injury [6], [10]. Therefore, serum creatinine values are poorly qualified to detect AKI in the early period after cardiac surgery [11]. The same is true for postoperative oliguria, which can be influenced by a myriad of factors including volume status and use of diuretics. At the very least, several hours are needed to define oliguria. Several attempts to treat AKI have failed, perhaps in part because therapies were initiated too late in the presence of an already established acute tubular necrosis (ATN) [12]. Therefore, identifying biomarkers to predict the development and severity of AKI early after cardiac surgery has been an important goal for over a decade. Several biomarkers including interleukin (IL)-18 [13], neutrophil gelatinase-associated lipocalin (NGAL) [14], cystatin c [15], and kidney injury molecule-1 (KIM-1) [16] have been studied. However, the area under the curve (AUC) and therefore the suitability of these biomarkers to predict AKI after cardiac surgery were fairly low (0.65 for KIM-1 [17], 0.67 for NGAL [17], and 0.71 for cystatin c [15]). AKI affects different complex cellular and molecular pathways involving inflammatory, interstitial, endothelial, and epithelial cells. These mechanisms comprise immunity, inflammation, apoptosis, and cell cycle pathways. A recent study showed that renal tubular cells enter a period of G1 cell-cycle arrest after inducing ischemia [18] or sepsis [19]. IGFBP7 and TIMP-2 are both involved in G1 cell cycle arrest during the early phase of cell injury [20]–[22]. The G1 cell cycle arrest may prevent the division of cells with damaged DNA until the DNA damage is repaired [21]. In the Sapphire study [23], it was demonstrated that the AUC values to predict the development of AKI (AKIN stage 2 or 3) in critically ill patients within 12 hours were 0.76 for IGFBP7 and 0.79 for TIMP-2. Multiplication of the two markers ([TIMP-2]*[IGFBP7]) resulted in an even higher AUC (0.80) and was significantly superior to all previously described markers of AKI. Moreover, [TIMP-2]*[IGFBP7] significantly improved risk prediction when added to clinical scoring systems. Therefore the aim of the current study was to test the hypothesis that urinary [TIMP-2]*[IGFBP7] can predict AKI early after cardiac surgery and that urinary [TIMP-2]*[IGFBP7] can function as a prognostic marker in patients with established AKI providing information about the likelihood of recovery. MATERIALS AND METHODS Patients and methods The study was approved by the institutional review board of the University of Münster. We used the Standards for Reporting of Diagnostic Accuracy (STARD) statement for planning and conducting the study and preparing the manuscript [24]. We screened all patients admitted to the University of Münster Cardiac Surgery service for cardiac surgery with CPB between June 2013 and September 2013 (Figure 1: CONSORT 2010 Flow Diagram). Patients with a Cleveland Clinic Foundation Score [8] of 6 or more were eligible for enrollment. All patients eligible for enrollment were approached. Exclusion criteria included (1) pregnancy; (2) post-renal transplantation; (3) immunosuppressive therapy; and (4) patients receiving corticosteroid therapy with a change in their dose within the past 2 weeks. Written informed consent was obtained from all patients at the time of enrollment. All patients were prospectively followed from enrollment. Urine samples were collected at predetermined time points: on the day of the surgery preoperatively (immediately post-anesthesia induction), 4 h, 12 h, and 24 h after coming off CPB. At the same time points, creatinine concentrations in the urine were measured. Serum creatinine levels were measured preoperatively, 4 h, 12 h, 24 h, 48 h, 72 h, and at the time of hospital discharge. All patients received routine standard of care during the study period. ICU and hospital discharge were conducted at the discretion of the treating clinicians, not involved in the study and not aware of study data. Cardiac function and volume status were ascertained by clinical judgment combined with transthoracic echocardiography (TTE). A TTE examination was performed routinely on all patients on the day of surgery (2 to 4 h after admission to the ICU) and on day 1 following surgery. Patients were considered to have completed the study at the time of hospital discharge. Urine samples were immediately centrifuged, urine supernatants were frozen, stored at ≤−70°C and thawed immediately prior to analysis. [Figure: CONSORT 2010 Flow Diagram.] Preoperative patient characteristics, significant intraoperative risk factors and peri- and postoperative complications were recorded. All clinical decisions were made by the responsible cardiac surgeon, cardiac anesthetist, and/or intensivist. Study